Non-regulatory
announcement
Verici Dx
plc
("Verici Dx" or the
"Company")
New data to be presented at
American Transplant Conference
Important potential role of
TutiviaTM as a novel risk assessment tool in the context
of delayed graft function ("DGF")
Verici Dx plc (AIM: VRCI), a
developer of advanced clinical diagnostics for organ
transplant, announces it will attend the American Transplant
Congress ("ATC") in Philadelphia hosted by the American Society of
Transplantation and the American Society of Transplant Surgeons
from 1-5 June 2024. We look forward to sharing our work on
"Performance of Next-Gen Sequencing
Biomarker TutiviaTM in the Setting of Kidney Delayed
Graft Function" on Saturday 1 June 2024, as
well as meeting with others to discuss ideas and opportunities at
ATC_Booth-215.
ATC provides a forum for the
exchange of new scientific data and clinical information relevant
to solid organ and tissue transplantation. The event brings
together transplant physicians, scientists, nurses, organ
procurement personnel, pharmacists, allied health professionals and
other transplant professionals.
Commenting on the conference, Dr. Joshua Lee, VP Medical
Affairs said:
"DGF is a condition that can lead to
a higher risk of rejection. Identifying which patients are likely
to experience rejection in this population is an unmet need in
transplantation. Verici Dx is excited to present findings in this
population from our clinical trial at this prestigious
conference.
ATC in Philadelphia is such a great
venue to bring together the global transplant community. We are
looking forward to discussions in the halls and seeing friends in
the community, as well as learning about new developing approaches
to treatments and diagnostics that can make the lives of transplant
patients better."
Enquiries:
|
Verici Dx
|
www.vericidx.com
|
|
|
Sara Barrington, CEO
|
investors@vericidx.com
|
|
|
Julian Baines, Chairman
|
|
|
|
|
|
|
|
|
|
|
|
Singer Capital Markets (Nominated Adviser &
Broker)
|
Tel: +44 20 7496
3000
|
|
|
Aubrey Powell / Sam
Butcher
|
|
|
|
|
|
About Verici Dx plc www.vericidx.com
Verici Dx is a developer of a
complementary suite of leading-edge tests forming a kidney
transplant platform for personalised patient and organ response
risk to assist clinicians in medical management for improved
patient outcomes. The underlying technology is based upon
artificial intelligence assisted transcriptomic analysis to provide
RNA signatures focused upon the immune response and other
biological pathway signals critical for transplant prognosis of
risk of injury, rejection and graft failure from pre-transplant to
late stage. The Company also has a mission to accelerate the pace
of innovation by research using the fully characterised data from
the underlying technology, including through collaboration with
medical device, biopharmaceutical and data science
partners.
The foundational research was driven
by a deep understanding of cell-mediated immunity and is enabled by
access to expertly curated collaborative studies in highly
informative cohorts in kidney transplant.